Evidence map›Paper›PMID 29301937›Full record

ArticleThe Journal of biological chemistry2018

Cyclipostins and cyclophostin analogs inhibit the antigen 85C from

Albertus Viljoen, Matthias Richard, Phuong Chi Nguyen, Patrick Fourquet, Luc Camoin, Rishi R Paudal, Giri R Gnawali, Christopher D Spilling, Jean-François Cavalier, Stéphane Canaan and 2 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Secreted proteins ofFrontiers in tuberculosis · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Azetidines Kill Multidrug-ResistantJournal of medicinal chemistry · 2024
    Article
  7. Potential therapeutic targets fromRSC medicinal chemistry · 2022
    Review
  8. Review
  9. Review
  10. Fragment-Based Design ofJournal of medicinal chemistry · 2020
    Article
  11. Article
  12. Review
  13. Article
  14. A piperidinol-containing molecule is active againstThe Journal of biological chemistry · 2019
    Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Albertus ViljoenInstitut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR9004, 34293 Montpellier, France.
Matthias RichardInstitut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR9004, 34293 Montpellier, France.
Phuong Chi NguyenAix-Marseille Université, CNRS, EIPL, IMM FR3479, 13009 Marseille, France; Aix-Marseille Université, CNRS, LISM, IMM FR3479, 13009 Marseille, France.
Patrick FourquetAix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille Protéomique, 13009 Marseille, France.
Luc CamoinAix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille Protéomique, 13009 Marseille, France.
Rishi R PaudalDepartment of Chemistry and Biochemistry, University of Missouri, St. Louis, Missouri 63121.
Giri R GnawaliDepartment of Chemistry and Biochemistry, University of Missouri, St. Louis, Missouri 63121.
Christopher D SpillingDepartment of Chemistry and Biochemistry, University of Missouri, St. Louis, Missouri 63121.
Jean-François CavalierAix-Marseille Université, CNRS, EIPL, IMM FR3479, 13009 Marseille, France; Aix-Marseille Université, CNRS, LISM, IMM FR3479, 13009 Marseille, France.
Stéphane CanaanAix-Marseille Université, CNRS, EIPL, IMM FR3479, 13009 Marseille, France; Aix-Marseille Université, CNRS, LISM, IMM FR3479, 13009 Marseille, France.
Mickael BlaiseInstitut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR9004, 34293 Montpellier, France. Electronic address: mickael.blaise@irim.cnrs.fr.
Laurent KremerInstitut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR9004, 34293 Montpellier, France; INSERM, IRIM, 34293 Montpellier, France. Electronic address: laurent.kremer@irim.cnrs.fr.
Laboratoire d'Ingénierie des Systèmes MacromoléculairesUniversity of Missouri–St. Louis · USUniversité de Montpellier · FRCentre National de la Recherche Scientifique · FRInstitut de Recherche en Infectiologie de Montpellier · FRInstitut Pprime · FRLaboratory of Pathogens and Host Immunity · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasing prevalence of cases of drug-resistant tuberculosis requires the development of more efficacious chemotherapies. We previously reported the discovery of a new class of cyclipostins and cyclophostin (CyC) analogs exhibiting potent activity against

Indexed as

Models, MolecularAcylationAcyltransferasesAmino Acid SubstitutionAntigens, BacterialAntitubercular AgentsBacterial ProteinsBinding SitesCatalytic DomainCrystallography, X-RayEnzyme InhibitorsLigandsMicrobial ViabilityMolecular ConformationMutationMycobacterium tuberculosisAcyltransferasesantigen 85A, Mycobacterium tuberculosisantigen 85B, Mycobacterium tuberculosisantigen 85C, Mycobacterium tuberculosisAntigens, BacterialAntitubercular AgentsBacterial ProteinsEnzyme InhibitorsLigandsMPT51 protein, MycobacteriumOrganophosphorus CompoundsRecombinant Fusion ProteinsSerineAg85 complexcell wallcrystal structurecyclipostinscyclophostininhibition mechanismMycobacterium tuberculosistrehalose dimycolatetrehalose monomycolatetriacylglycerol

Identifiers

PMID29301937
PMCPMC5827452
OpenAlexW2782476479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.